|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.89 USD | +1.58% |
|
+5.48% | +16.34% |
| Capitalization | 10.38B 8.83B 8.18B 7.64B 14.25B 953B 15.1B 93.49B 37.12B 450B 38.91B 38.12B 1,637B | P/E ratio 2025 * |
17x | P/E ratio 2026 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise value | 9.54B 8.11B 7.52B 7.03B 13.1B 876B 13.88B 85.93B 34.11B 414B 35.76B 35.03B 1,505B | EV / Sales 2025 * |
0.21x | EV / Sales 2026 * | 0.19x |
| Free-Float |
99.89% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Molina Healthcare, Inc.
| 1 day | +1.58% | ||
| 1 week | +5.48% | ||
| Current month | +16.34% | ||
| 1 month | +23.09% | ||
| 3 months | +25.40% | ||
| 6 months | +6.12% | ||
| Current year | +16.34% |
| 1 week | 183.78 |  | 202.46 |
| 1 month | 162.19 | | 202.46 |
| Current year | 171.24 | | 202.46 |
| 1 year | 133.4 | | 359.97 |
| 3 years | 133.4 | | 423.92 |
| 5 years | 133.4 | | 423.92 |
| 10 years | 42.56 | | 423.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joe Zubretsky
CEO | Chief Executive Officer | 69 | 06/11/2017 |
Mark Keim
DFI | Director of Finance/CFO | 60 | 17/02/2021 |
Jason Dees
CTO | Chief Tech/Sci/R&D Officer | - | 09/01/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronna Romney
BRD | Director/Board Member | 82 | 01/01/1999 |
Steven Orlando
BRD | Director/Board Member | 74 | 04/11/2005 |
Dale Wolf
CHM | Chairman | 72 | 02/05/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 2.6% | 4 M€ | |
| 0.00% | 1.82% | 2 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.58% | +5.48% | -34.10% | -32.09% | 10.38B | |
| +0.50% | +7.62% | -32.75% | -26.67% | 323B | |
| -0.32% | -1.02% | -7.55% | -22.36% | 82.46B | |
| -0.42% | +2.57% | -5.35% | -9.40% | 74.58B | |
| +0.08% | -2.48% | -9.29% | -46.11% | 32.05B | |
| +1.48% | +0.74% | -29.22% | -39.19% | 22.65B | |
| +0.85% | +5.82% | +63.42% | +94.05% | 4.76B | |
| +0.88% | +2.85% | +14.53% | -24.78% | 2.17B | |
| Average | +0.44% | +1.25% | -5.04% | -13.32% | 68.97B | |
| Weighted average by Cap. | -0.36% | +3.84% | -22.78% | -24.39% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 44.97B 38.25B 35.45B 33.13B 61.76B 4,132B 65.46B 405B 161B 1,951B 169B 165B 7,096B | 46.79B 39.79B 36.88B 34.47B 64.25B 4,298B 68.1B 422B 167B 2,030B 175B 172B 7,383B |
| Net income | 631M 537M 498M 465M 867M 57.99B 919M 5.69B 2.26B 27.38B 2.37B 2.32B 99.59B | 619M 527M 488M 456M 850M 56.89B 901M 5.58B 2.21B 26.86B 2.32B 2.27B 97.72B |
| Net Debt | -840M -714M -662M -619M -1.15B -77.14B -1.22B -7.56B -3B -36.42B -3.15B -3.08B -132B | -1.26B -1.07B -995M -930M -1.73B -116B -1.84B -11.38B -4.52B -54.78B -4.74B -4.64B -199B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 201.89 $ | +1.58% | 911,437 |
| 22/01/26 | 198.75 $ | +2.13% | 1,075,437 |
| 21/01/26 | 194.60 $ | +1.74% | 1,040,719 |
| 20/01/26 | 191.27 $ | -0.07% | 1,260,705 |
| 16/01/26 | 191.40 $ | -1.21% | 930,381 |
Delayed Quote Nyse, 24 January 2026 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MOH Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition